FDA fast tracks blockbuster diabetes drug for heart failure
FDA granted Fast Track designation to a popular diabetes drug to reduce the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure.
Eid
FDA granted Fast Track designation to empagliflozin (Jardiance, Boehringer Ingelheim and Eli Lilly and Company) to reduce the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure.
The once-daily tablet Jardiance is a popular medication that treats type 2 diabetes.
Related: FDA Warns Maker Of Ingredient In Huge Heart Drug Recall
“Heart failure contributes to 1 in 9 deaths and is a leading cause of hospitalization in the U.S., yet there are limited treatment options for people living with this debilitating disease,” said Mohamed Eid, MD, MPH, vice president of clinical development & medical affairs for Boehringer Ingelheim, in a statement from the company. “The FDA Fast Track designation for empagliflozin is an important step forward in addressing this unmet need, and we look forward to working closely with the FDA as we explore the potential for empagliflozin to improve outcomes for adults with chronic heart failure."
Already affecting 26 million people worldwide, including more than 6.5 million in the U.S., heart failure is expected to become even more prevalent, Boehringer Ingelheim said.
Related: Top 4 Drugs In The Pipeline
This designation is for the ongoing EMPEROR program, which consists of the EMPEROR-Reduced and EMPEROR-Preserved studies. The studies will evaluate the effect of empagliflozin on cardiovascular death and hospitalization for heart failure in adults with chronic heart failure with reduced or preserved ejection fraction.
The two EMPEROR phase 3 studies include more than 8,500 people with chronic heart failure.
Read more: Cybersecurity Glitch Wreaks Havoc On Insulin Pumps
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Diabetes Management & Telehealth with Leslie Kolb
August 2nd 2025Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
August 2nd 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
August 2nd 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
